In the area of peptide and protein pharmaceuticals, both the physical and chemical stability of biopharmaceuticals are critical and need to be optimised when formulating a drug product, in order to optimise the outcome after processing and storage. This review focuses on the effects on the stability from various types of excipient and the choices that have to be made during formulation of drug products containing peptides or proteins. It is illustrated, through examples, how the choice of one excipient over another can affect the stability of a protein drug formulation, along with other problems linked to this choice. The excipients used in pharmaceutical preparations are limited and from an academic point of view there is a clear requirement for new excipients.

No abstract

No abstract

No abstract

No abstract

Protein pharmaceuticals have matured into an important class of drugs, now comprising one in three novel drugs introduced on the market. However, significant gains are still to be made in reducing the costs of production, ensuring proper pharmacokinetics and efficacy, increasing patient compliance and convenience, and reducing side effects such as immunogenicity. This review summarises these issues and provides recent examples of methods to reduce costs, alter pharmacokinetics and increase patient compliance. It also discusses the increasing interest in understanding immunogenicity in order to prevent failure of the protein drug or serious life-threatening side effects due to autoimmunogenicity.

No abstract

Ghrelin is a pharmacologically interesting peptide hormone due to its effects on appetite and metabolism. The cationic, octanoylated 28 amino acid peptide has a short biological half-life; thus, prolonged release formulations are of interest. Acylated peptides have been suggested to bind to or be incorporated into liposomes. Formulations based on neutral dipalmitoylphosphatidylcholine (DPPC) liposomes and phosphatidylcholine:cholesterol (70:30 mol%) liposomes, and negatively charged dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylserine (DPPC:DPPS) (70:30 mol%) liposomes (2 mM total lipid concentration) were characterized using ACE. Pre-equilibrium CZE and frontal analysis CE methods circumventing capillary wall adsorption of the peptide and the liposomes and suitable for characterizing ghrelin-liposome interactions were developed. The cationic peptide exhibited low affinity (<10% bound) for DPPC and phosphatidylcholine:cholesterol (70:30 mol%) liposomes whereas electrostatic interactions caused a higher affinity for DPPC:DPPS (70:30 mol%) liposomes. Studies on desacyl ghrelin instead of ghrelin demonstrated the significance of the n-octanoyl side chain as an affinity providing moiety towards DPPC:DPPS liposomes (48 and 73% bound peptide, respectively). CE experiments showed that the binding was characterized by rapid dissociation kinetics.